0JDM.L StockTwits Mentions

Track 0JDM.L's AI-powered predictions, market trends, and investment insights.

0JDM.L AI Prediction 0JDM.L Sentiment 0JDM.L Reddit

Mock Tradesimulated, no real money

You don't hold 0JDM.L in your mock portfolio yet.

0JDM.L StockTwits Mentions

Track 0JDM.L's AI-powered predictions, market trends, and investment insights.

0JDM.L AI Prediction 0JDM.L Sentiment 0JDM.L Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-1.3%

Price (7d)-2.5%

Volume vs avg0.2x

Reddit mentions vs 7D-9%

Volatility vs normal0.7x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 1K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~$163.99 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

0JDM.L AI Stock Analysis

Financial Performance

neutral

With EPS of 5.54 and a PE of 30.41, IQVIA is priced at a premium multiple that implies solid, but not explosive, earnings expectations. The valuation suggests investors still view the business as a high‑quality, secular growth name, but the multiple is not cheap relative to broader markets or many large-cap healthcare peers. Without additional evidence of accelerating earnings growth, the risk/reward from fundamentals alone appears balanced rather than clearly compelling.

EPS of 5.54 supports a meaningful earnings base, but the current valuation (PE 30.41) prices in continued growth and resilience, leaving less margin of safety if growth slows.
A PE above the market average implies investors expect durable revenue and profit expansion from IQVIA’s data and clinical solutions franchise, consistent with its positioning in life sciences and healthcare analytics.
Given the elevated multiple and absence of clear evidence of recent earnings acceleration in the provided data, the fundamental picture skews toward fairly valued rather than obviously undervalued or overextended.

Stock Price & Technicals

bearish

Despite a 4.1% gain over the last month, the stock at $168.36 is trading well below its 200‑day moving average of $214.61, indicating a longer‑term downtrend or substantial prior drawdown. The gap between price and the 200‑day average suggests the stock remains technically weak, with rallies occurring within a broader corrective phase. Without signs that price is reclaiming and holding above key moving averages, the technical backdrop leans negative.

Current price of $168.36 is significantly below the 200‑day moving average of $214.61, a classic sign of a stock in a longer‑term downtrend or under distribution.
The recent 4.1% one‑month gain indicates short‑term buying interest, but it has not yet reversed the broader technical damage implied by the large discount to the 200‑day average.
At a PE of 30.41 while trading below its long‑term average, the stock combines a premium valuation with weak technicals, which can limit near‑term upside until the trend stabilizes and the price begins to close the gap with the 200‑day moving average.

Alternative Data Signals

bullish

Alternative data for IQVIA points to healthy underlying business activity and engagement. Strong web traffic, robust daily app downloads, and a sharp increase in job openings suggest ongoing investment in growth and demand for the company’s services. While social media follower growth is modest on most platforms, the very large LinkedIn base underscores IQVIA’s entrenched position in the professional life sciences ecosystem.

Estimated web traffic of 1,167,460 monthly visitors and roughly 10,000 mobile app downloads per day indicate active user engagement with IQVIA’s digital products and services, a positive sign for pipeline and client interaction.
Job openings at 3,000, up 50% month over month, are a strong leading indicator of expansion—implying the company is scaling operations, investing in capacity, and likely anticipating continued or rising demand.
Social media metrics show modest growth on Twitter/X (+0.1%), Instagram (+2.9%), and Facebook (+0.2%) over 90 days, but the standout figure is 2,598,942 LinkedIn followers, reflecting deep professional reach and brand strength in its core B2B markets even if consumer‑facing growth is incremental.

Conclusion

neutral

IQVIA’s alternative data profile and earnings base support a constructive long‑term business outlook, but the stock’s technical position and premium valuation temper the near‑term view. The shares trade well below their 200‑day moving average while still commanding a high multiple, suggesting investors remain cautious despite underlying operational strength. Overall, the balance of signals points to a neutral stance: the business appears fundamentally solid with growth investments underway, but the stock may need more time to repair its technical profile or deliver stronger earnings momentum before a clearer bullish case emerges.

Operational and alternative data (traffic, app downloads, hiring) are supportive and lean bullish, indicating IQVIA is investing for and experiencing ongoing demand.
Technical weakness and a still‑elevated valuation offset these positives, leading to a neutral overall view on the stock’s risk/reward in the near term.

AI Score

Hold

Alternative7

Fundamental3

Technical6

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold 0JDM.L in your mock portfolio yet.